RU2002101935A - Amine and amide derivatives as ligands for the neuropeptide Y receptor Y5 used to treat obesity and other disorders - Google Patents

Amine and amide derivatives as ligands for the neuropeptide Y receptor Y5 used to treat obesity and other disorders

Info

Publication number
RU2002101935A
RU2002101935A RU2002101935/04A RU2002101935A RU2002101935A RU 2002101935 A RU2002101935 A RU 2002101935A RU 2002101935/04 A RU2002101935/04 A RU 2002101935/04A RU 2002101935 A RU2002101935 A RU 2002101935A RU 2002101935 A RU2002101935 A RU 2002101935A
Authority
RU
Russia
Prior art keywords
substituted
aryl
methylene
group
amino
Prior art date
Application number
RU2002101935/04A
Other languages
Russian (ru)
Other versions
RU2228927C2 (en
Inventor
Скотт Л. Дакс
Джеймс МакНАЛЛИ
Марк ЯНГМАН
Original Assignee
Орто-Макнейл Фармасьютикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Орто-Макнейл Фармасьютикал, Инк. filed Critical Орто-Макнейл Фармасьютикал, Инк.
Publication of RU2002101935A publication Critical patent/RU2002101935A/en
Application granted granted Critical
Publication of RU2228927C2 publication Critical patent/RU2228927C2/en

Links

Claims (16)

1. Соединение формулы:1. The compound of the formula:
Figure 00000001
Figure 00000001
 где R 1 независимо выбран из группы, состоящей из водорода, гидрокси, галогена, C 1-8 алкила, замещенного C 1-8 алкила, C 1-8 алкокси, замещенного C 1-8 алкокси, трифторалкила, C 1-8 алкилтио, замещенного C 1-8 алкилтио, С 3-8 циклоалкила, С 3-8 циклоалкокси, нитро, амино, C 1-6 алкиламино, С 1-8 диалкиламино, С 4-8 циклоалкиламино, циано, карбокси, С 1-5 алкоксикарбонила, С 1-5 алкилкарбонилокси, формила, карбамоила, фенила и замещенного фенила; where R 1 is independently selected from the group consisting of hydrogen, hydroxy, halogen, C 1-8 alkyl, substituted C 1-8 alkyl, C 1-8 alkoxy, substituted C 1-8 alkoxy, trifluoroalkyl, C 1-8 alkylthio, substituted C 1-8 alkylthio, C 3-8 cycloalkyl, C 3-8 cycloalkoxy, nitro, amino, C 1-6 alkylamino, C 1-8 dialkylamino, C 4-8 cycloalkylamino, cyano, carboxy, C 1-5 alkoxycarbonyl C 1-5 alkylcarbonyloxy, formyl, carbamoyl, phenyl and substituted phenyl; n = 1-2;n is 1-2; B1 представляет водород;B 1 represents hydrogen; B2 представляет водород; либо B1 и B2 представляют метилен и, взятые вместе, образуют пяти- или шестичленное кольцо;B 2 represents hydrogen; either B 1 and B 2 represent methylene and, taken together, form a five- or six-membered ring; m = 0-3;m is 0-3; R2 независимо выбран из группы, состоящей из водорода, гидрокси, C1-6алкила, С2-6алкенила, галогена, С3-7циклоалкила, фенила, замещенного фенила, нафтила, замещенного нафтила, фенокси, замещенного фенокси, гетероарила, замещенного гетероариала и гетероциклоалкила;R 2 is independently selected from the group consisting of hydrogen, hydroxy, C 1-6 alkyl, C 2-6 alkenyl, halogen, C 3-7 cycloalkyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, phenoxy, substituted phenoxy, heteroaryl, substituted heteroaryl and heterocycloalkyl; L выбран из группы, состоящей из C1-8алкилена, С2-10алкенилена, С2-10алкинилена, С3-7циклоалкилена, С3-7циклоалкилС1-4алкилена, арил С1-4алкилена, α-аминоC4-7алкилена;L is selected from the group consisting of C 1-8 alkylene, C 2-10 alkenylene, C 2-10 alkynylene, C 3-7 cycloalkylene, C 3-7 cycloalkyl C 1-4 alkylene, aryl C 1-4 alkylene, α- amino C 4-7 alkylene;
Figure 00000002
Figure 00000002
 (N-метилен)пиперидин-4-ила;(N-methylene) piperidin-4-yl;
Figure 00000003
Figure 00000003
 (N-метилен)пиперазин-4-ила;(N-methylene) piperazin-4-yl;
Figure 00000004
Figure 00000004
 (N-метилен)пирролидин-3-ила;(N-methylene) pyrrolidin-3-yl;
Figure 00000005
Figure 00000005
 (N-метилен)-4-ацетилпиперидин-4-ила;(N-methylene) -4-acetylpiperidin-4-yl;
Figure 00000006
Figure 00000006
 и (N-метилен)пиперидин-4,4-диила;and (N-methylene) piperidin-4,4-diyl;
Figure 00000007
Figure 00000007
 Y представляет метилен или карбонил;Y represents methylene or carbonyl; Z выбран из группы, состоящей из арила;Z is selected from the group consisting of aryl;
Figure 00000008
Figure 00000008
 N-сульфонамидо;N-sulfonamido;
Figure 00000009
Figure 00000009
 N-(арил)сульфонамидо;N- (aryl) sulfonamido;
Figure 00000010
Figure 00000010
 ариламидо;arylamido;
Figure 00000011
Figure 00000011
 арилуреидо;arylureido;
Figure 00000012
Figure 00000012
 арилацетамидо;aryl acetamido;
Figure 00000013
Figure 00000013
 (арилокси)карбониламино;(aryloxy) carbonylamino;
Figure 00000014
Figure 00000014
 2,3-дигидро-2-оксо-1Н-бензимидазол-1-ила;2,3-dihydro-2-oxo-1H-benzimidazol-1-yl;
Figure 00000015
Figure 00000015
 и 1-арил-2,3-дигидро-4-оксо-имидазол-5,5-диила;and 1-aryl-2,3-dihydro-4-oxo-imidazole-5,5-diyl;
Figure 00000016
Figure 00000016
 R3 независимо выбран из группы, состоящей из C1-6алкила, замещенного C1-6алкила, циклоалкила, замещенного циклоалкила, нафтила, замещенного нафтила, гетероарила и замещенного гетероарила;R 3 is independently selected from the group consisting of C 1-6 alkyl, substituted C 1-6 alkyl, cycloalkyl, substituted cycloalkyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl; R4 независимо выбран из группы, состоящей из водорода, С1-8алкила, C1-6алкокси, замещенного C1-8алкокси, гидрокси, галогена, циано, нитро, амино, C1-6алкиламино и С2-8диалкиламино;R 4 is independently selected from the group consisting of hydrogen, C 1-8 alkyl, C 1-6 alkoxy, substituted C 1-8 alkoxy, hydroxy, halogen, cyano, nitro, amino, C 1-6 alkylamino and C 2-8 dialkylamino; R5 независимо выбран из группы, состоящей из водорода, C1-6алкила, C1-8алкилкарбонила, ароила, карбамоила, амидино, C1-8алкила, С1-8алкиламинокарбонила, (ариламино)карбонила и арил С2-8алкилкарбонила;R 5 is independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-8 alkylcarbonyl, aroyl, carbamoyl, amidino, C 1-8 alkyl, C 1-8 alkylaminocarbonyl, (arylamino) carbonyl and aryl C 2- 8 alkylcarbonyl; R6 независимо выбран из водорода и С1-8алкила;R 6 is independently selected from hydrogen and C 1-8 alkyl; р = 1-3;p = 1-3; q = 1-3;q is 1-3; и его энантиомеры, диастереомеры и фармацевтически приемлемые соли,and its enantiomers, diastereomers and pharmaceutically acceptable salts, при условии, что если L представляет C1-6алкилен, С2-10алкенилен, С2-10алкинилен, С3-7циклоалкилен, С3-7циклоалкилС1-4алкилен, арилС1-4алкилен или α-аминоС4-7алкилен, то Z представляет фенил, N-сульфонамидо или N-(арил)сульфонамидо; если L представляет (N-метилен)пиперазин-4-ил, то Z представляет фенил или нафтил; если L представляет (N-метилен)пирролидин-3-ил или (N-метилен)пиперидин-4-ил, то Z представляет N-сульфонамидо, N-(арил)сульфонамидо, 2,3-дигидро-2-оксо-1Н-бензимидазол-1-ил, бензамидо, фенилуреидо, фенилацетамидо или (фенокси)-карбониламино; если L представляет (N-метилен)-4-ацетилпиперидин-4-ил, то Z представляет фенил или нафтил, a Y представляет карбонил; если L представляет (N-метилен)пиперидин-4,4-диил, то Z представляет 1-арил-2,3-дигидро-4-оксоимидазол-5,5-диил, а Y представляет карбонил; и если B1 и В3 оба представляют метилен, образуя, таким образом шестичленное кольцо, и если L представляет C1-10алкилен, С2-10алкенилен, C2-10алкинилен или арил С1-4алкилен, то Z не является N-сульфонамидо, N-(арил)сульфонамидо или фенилом.with the proviso that if L is C 1-6 alkylene, C 2-10 alkenylene, C 2-10 alkynylene, C 3-7 cycloalkylene, C 3-7 cycloalkyl C 1-4 alkylene, aryl C 1-4 alkylene or α-aminoC 4-7 alkylene, then Z represents phenyl, N-sulfonamido or N- (aryl) sulfonamido; if L is (N-methylene) piperazin-4-yl, then Z is phenyl or naphthyl; if L is (N-methylene) pyrrolidin-3-yl or (N-methylene) piperidin-4-yl, then Z is N-sulfonamido, N- (aryl) sulfonamido, 2,3-dihydro-2-oxo-1H -benzimidazol-1-yl, benzamido, phenylureido, phenylacetamido or (phenoxy) -carbonylamino; if L is (N-methylene) -4-acetylpiperidin-4-yl, then Z is phenyl or naphthyl, and Y is carbonyl; if L is (N-methylene) piperidin-4,4-diyl, then Z is 1-aryl-2,3-dihydro-4-oxoimidazole-5,5-diyl, and Y is carbonyl; and if B 1 and B 3 both represent methylene, thus forming a six-membered ring, and if L represents C 1-10 alkylene, C 2-10 alkenylene, C 2-10 alkynylene or aryl C 1-4 alkylene, then Z is not is N-sulfonamido, N- (aryl) sulfonamido or phenyl. 2. Соединение по п.1, где R1 представляет Н, алкил, замещенный алкил, алкокси, галоген, замещенный алкокси, гидрокси, трифторалкил, нитро, амино, алкиламино, циклоалкиламино, циано, карбокси, циклоалкил, фенил и замещенный фенил; R2 представляет Н, гидрокси, алкил, замещенный алкил, галоген, гетероциклоалкил, гетероарил, фенил, замещенный фенил, нафтил и замещенный нафтил; B1 представляет водород; В2 представляет водород, либо B1 и B2 представляют метилен и, взятые вместе, образуют пяти- или шестичленное кольцо; Y представляет метилен или карбонил; Z выбран из группы, состоящей из арила, замещенного арила, N-сульфонамидо, N-(арил)сульфонамидо, замещенного N-(арил)сульфонамидо, арилмидо, замещенного арилмидо, арилуреидо, замещенного арилуреидо, арилацетамидо, замещенного арилацетамидо, (арилокси)карбониламино, замещенного (арилокси)карбониламино, 2,3-дигидро-2-оксо-1Н-бензимидазол-1-ила, замещенного 2,3-дигидро-2-оксо-1Н-бензимидазол-1-ила, 1-арил-2,3-дигидро-4-оксо-имидазол-5,5-диила и замещенного 1-арил-2,3-дигидро-4-оксо-имидазол-5,5-диила; L представляет C1-6алкилен, С2-10алкенилен, С2-10алкинилен, С3-6циклоалкилен, С3-7циклоалкилС1-4алкилен, арилС1-4алкилен, α-аминоС4-7алкилен, (N-метилен)пиперидин-4-ил, замещенный (N-метилен)пиперидин-4-ил, (N-метилен)пиперазин-4-ил, (N-метилен)пирролидин-3-ил, (N-метилен)-4-ацетил-пиперидин-4-ил и (N-метилен)пиперидин-4,4-диил; n = 1-2; m = 1-3; р = 1-3 и q = 1-3.2. The compound according to claim 1, where R 1 represents H, alkyl, substituted alkyl, alkoxy, halogen, substituted alkoxy, hydroxy, trifluoroalkyl, nitro, amino, alkylamino, cycloalkylamino, cyano, carboxy, cycloalkyl, phenyl and substituted phenyl; R 2 represents H, hydroxy, alkyl, substituted alkyl, halogen, heterocycloalkyl, heteroaryl, phenyl, substituted phenyl, naphthyl and substituted naphthyl; B 1 represents hydrogen; B 2 represents hydrogen, or B 1 and B 2 represent methylene and, taken together, form a five- or six-membered ring; Y represents methylene or carbonyl; Z is selected from the group consisting of aryl, substituted aryl, N-sulfonamido, N- (aryl) sulfonamido, substituted N- (aryl) sulfonamido, arylmido, substituted arylmido, arylureido, substituted arylureido, aryl acetamido, substituted aryl acetamido, aryl aryl substituted (aryloxy) carbonylamino, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl, substituted 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl, 1-aryl-2, 3-dihydro-4-oxo-imidazole-5,5-diyl and substituted 1-aryl-2,3-dihydro-4-oxo-imidazole-5,5-diyl; L represents C 1-6 alkylene, C 2-10 alkenylene, C 2-10 alkynylene, C 3-6 cycloalkylene, C 3-7 cycloalkyl C 1-4 alkylene, aryl C 1-4 alkylene, α-amino C 4-7 alkylene, (N-methylene) piperidin-4-yl, substituted (N-methylene) piperidin-4-yl, (N-methylene) piperazin-4-yl, (N-methylene) pyrrolidin-3-yl, (N-methylene) -4-acetyl-piperidin-4-yl and (N-methylene) piperidin-4,4-diyl; n is 1-2; m is 1-3; p = 1-3 and q = 1-3. 3. Соединение по п.1, выбранное из группы, состоящей из3. The compound according to claim 1, selected from the group consisting of
Figure 00000017
Figure 00000017
Figure 00000018
Figure 00000018
Figure 00000019
Figure 00000019
Figure 00000020
и
Figure 00000020
and
Figure 00000021
Figure 00000021
 4. Соединение по п.1, выбранное из группы, состоящей из4. The compound according to claim 1, selected from the group consisting of
Figure 00000022
Figure 00000022
Figure 00000023
Figure 00000023
Figure 00000024
Figure 00000024
Figure 00000025
Figure 00000025
 и and
Figure 00000027
Figure 00000027
 5. Соединение по п.1, выбранное из группы, состоящей из5. The compound according to claim 1, selected from the group consisting of
Figure 00000028
Figure 00000028
Figure 00000029
Figure 00000029
Figure 00000030
Figure 00000030
Figure 00000031
Figure 00000031
Figure 00000032
и
Figure 00000032
and
Figure 00000033
Figure 00000033
 6. Соединение по п.1, выбранное из группы, состоящей из6. The compound according to claim 1, selected from the group consisting of
Figure 00000034
Figure 00000034
Figure 00000035
Figure 00000035
Figure 00000036
Figure 00000036
Figure 00000037
Figure 00000037
Figure 00000038
и
Figure 00000038
and
Figure 00000039
Figure 00000039
 7. Соединение по п.1, выбранное из группы, состоящей из7. The compound according to claim 1, selected from the group consisting of
Figure 00000040
Figure 00000040
Figure 00000041
Figure 00000041
Figure 00000042
Figure 00000042
Figure 00000043
Figure 00000043
Figure 00000044
и
Figure 00000044
and
Figure 00000045
Figure 00000045
 8. Соединение по п.1, выбранное из группы, состоящей из 8. The compound according to claim 1, selected from the group consisting of
Figure 00000046
Figure 00000046
Figure 00000047
Figure 00000047
Figure 00000048
Figure 00000048
Figure 00000049
и
Figure 00000049
and
Figure 00000050
Figure 00000050
 9. Соединение по п.1, выбранное из группы, состоящей из9. The compound according to claim 1, selected from the group consisting of
Figure 00000051
Figure 00000051
Figure 00000052
Figure 00000052
Figure 00000053
Figure 00000053
Figure 00000054
и
Figure 00000054
and
Figure 00000055
Figure 00000055
 10. Соединение по п.1, выбранное из группы, состоящей из10. The compound according to claim 1, selected from the group consisting of
Figure 00000056
Figure 00000056
Figure 00000057
Figure 00000057
Figure 00000058
Figure 00000058
Figure 00000059
Figure 00000059
Figure 00000060
и
Figure 00000060
and
Figure 00000061
Figure 00000061
 11. Соединение по п.1, выбранное из группы, состоящей из11. The compound according to claim 1, selected from the group consisting of
Figure 00000062
Figure 00000062
Figure 00000063
Figure 00000063
Figure 00000064
Figure 00000064
Figure 00000065
Figure 00000065
Figure 00000066
и
Figure 00000066
and
Figure 00000067
Figure 00000067
 12. Соединение по п.1, выбранное из группы, состоящей из12. The compound according to claim 1, selected from the group consisting of
Figure 00000068
Figure 00000068
Figure 00000069
Figure 00000069
Figure 00000070
Figure 00000070
Figure 00000071
Figure 00000071
Figure 00000072
Figure 00000072
Figure 00000073
и
Figure 00000073
and
Figure 00000074
Figure 00000074
 13. Соединение по п.1, выбранное из группы, состоящей из: 2-амино-6-[(2-фторфенилсульфонил)амино]-N-[цис-1,2,3,4-тетрагидро-6-метокси-1-(3-пиридинилметил)-2-нафтенил-(2S)-гексанамида бис-гидрохлорида;13. The compound according to claim 1, selected from the group consisting of: 2-amino-6 - [(2-fluorophenylsulfonyl) amino] -N- [cis-1,2,3,4-tetrahydro-6-methoxy-1 - (3-pyridinylmethyl) -2-naphthenyl- (2S) -hexanamide bis hydrochloride; N-[5-амино-6-[[цис-1,2,3,4-тетрагидро-6-метокси-1-(3-пиридинилметил)-2-нафталенил]амино]гексил-2-фторбензолсульфонамида трис-гидрохлорида;N- [5-amino-6 - [[cis-1,2,3,4-tetrahydro-6-methoxy-1- (3-pyridinylmethyl) -2-naphthalenyl] amino] hexyl-2-fluorobenzenesulfonamide tris hydrochloride; N-[5-амино-6-[[цис-1,2,3,4-тетрагидро-6-гидрокси-1-(3-пиридинилметил)-2-нафталенил]амино]гексил-2-фторбензол-сульфонамида трис-гидрохлорида;N- [5-amino-6 - [[cis-1,2,3,4-tetrahydro-6-hydroxy-1- (3-pyridinylmethyl) -2-naphthalenyl] amino] hexyl-2-fluorobenzene-sulfonamide tris- hydrochloride; (2S)-2-(ацетиламино)-6-[(2-фторфенилсульфонил)-амино]-N-[цис-1,2,3,4-тетрагидро-6-метокси-1-(3-пиридинилметил)-2-нафтенил]гексанамида бис-гидрохлорида;(2S) -2- (acetylamino) -6 - [(2-fluorophenylsulfonyl) amino] -N- [cis-1,2,3,4-tetrahydro-6-methoxy-1- (3-pyridinylmethyl) -2 naphthenyl] hexanamide bis hydrochloride; (2S)-2-(ацетиламино)-6-[(2-фторфенилсульфонил)-амино]-N-[цис-1,2,3,4-тетрагидро-6-гидрокси-1-(3-пиридинилметил)-2-нафтенил]гексанамида бис-гидрохлорида;(2S) -2- (acetylamino) -6 - [(2-fluorophenylsulfonyl) amino] -N- [cis-1,2,3,4-tetrahydro-6-hydroxy-1- (3-pyridinylmethyl) -2 naphthenyl] hexanamide bis hydrochloride; 3-[(фенилсульфонил)амино)-N-[цис-1,2,3,4-тетра-гидро-6-фтор-1-(3-пиридинилметил)-2-нафталенил]-1-пирролидинацетамида бис-трифторацетат;3 - [(phenylsulfonyl) amino) -N- [cis-1,2,3,4-tetra-hydro-6-fluoro-1- (3-pyridinylmethyl) -2-naphthalenyl] -1-pyrrolidinacetamide bis-trifluoroacetate; 4-(2,3-дигидро-2-оксо-1Н-бензимидазол-1-ил)-N-[цис-1,2,3,4-тетрагидро-6-метокси-1-(3-пиридинилметил)-2-нафталенил]-1-пиперидинацетамида бис-гидро-хлорида;4- (2,3-dihydro-2-oxo-1H-benzimidazol-1-yl) -N- [cis-1,2,3,4-tetrahydro-6-methoxy-1- (3-pyridinylmethyl) -2 naphthalenyl] -1-piperidinacetamide bis-hydrochloride; 4-(2,3-дигидро-2-оксо-1Н-бензимидазол-1-ил)-N-[транс-1,2,3,4-тетрагидро-6-метокси-1-(3-пиридинилметил)-2-нафталенил]-1-пиперидинацетамида бис-гидрохлорида;4- (2,3-dihydro-2-oxo-1H-benzimidazol-1-yl) -N- [trans-1,2,3,4-tetrahydro-6-methoxy-1- (3-pyridinylmethyl) -2 naphthalenyl] -1-piperidinacetamide bis hydrochloride; 4-ацетил-4-фенил-N-[цис-1,2,3,4-тетрагидро-1-(3-пиридинилметил)-2-нафталенил]-1-пиперидинацетамида бис-гидрохлорида;4-acetyl-4-phenyl-N- [cis-1,2,3,4-tetrahydro-1- (3-pyridinylmethyl) -2-naphthalenyl] -1-piperidineacetamide bis hydrochloride; 4-оксо-1-фенил-N-[цис-1,2,3,4-тетрагидро-1-(3-пиридинилметил)-2-нафталенил]-1,3,8-триазаспиро[4.5]декан-8-ацетамида бис-гидрохлорида;4-oxo-1-phenyl-N- [cis-1,2,3,4-tetrahydro-1- (3-pyridinylmethyl) -2-naphthalenyl] -1,3,8-triazaspiro [4.5] decan-8- acetamide bis hydrochloride; 4-(2,3-дигидро-2-оксо-1Н-бензимидазол-1-ил)-N-[цис-1,2,3,4-тетрагидро-6-гидрокси-1-(3-пиридинилметил)-2-нафталенил]-1-пиперидинацетамида бис-гидрохлорида;4- (2,3-dihydro-2-oxo-1H-benzimidazol-1-yl) -N- [cis-1,2,3,4-tetrahydro-6-hydroxy-1- (3-pyridinylmethyl) -2 naphthalenyl] -1-piperidinacetamide bis hydrochloride; транс-N-[2-(4-фторфенил)-3-(3-пиридинил)пропил]-4-[((2-фторфенилсульфонил)амино)метил]-1-циклогексанамида гидрохлорида;trans-N- [2- (4-fluorophenyl) -3- (3-pyridinyl) propyl] -4 - [((2-fluorophenylsulfonyl) amino) methyl] -1-cyclohexanamide hydrochloride; транс-N-[[[2-(4-фторфенил)3-(3-пиридинил)пропил]-амино]метил]-4-циклогексил]метил]-2-фторбензолсульфонамида бис-гидрохлорида;trans-N - [[[2- (4-fluorophenyl) 3- (3-pyridinyl) propyl] amino] methyl] -4-cyclohexyl] methyl] -2-fluorobenzenesulfonamide bis hydrochloride; N-[2-(4-фторфенил)-3-(3-пиридинил)пропил]-4-[(2-фторфенилсульфонил)амино]-1-пиперидинацетамида бис-трифторацетата.N- [2- (4-fluorophenyl) -3- (3-pyridinyl) propyl] -4 - [(2-fluorophenylsulfonyl) amino] -1-piperidineacetamide bis-trifluoroacetate. 14. Способ лечения расстройств и заболеваний, ассоциированных с рецептором подтипа 5 нейропептида NPY, предусматривающий введение млекопитающему, нуждающемуся в таком лечении, терапевтически эффективного количества соединения по п.1.14. A method for treating disorders and diseases associated with a subtype 5 receptor of an NPY neuropeptide, the method comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claim 1. 15. Фармацевтическая композиция для лечения заболеваний или расстройств, ассоциированных с рецептором подтипа Y5 нейропептида NPY, содержащая терапевтически эффективное количество соединения по п.1 и фармацевтически приемлемый носитель.15. A pharmaceutical composition for treating diseases or disorders associated with the NP5 neuropeptide subtype receptor Y5, comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier. 16. Фармацевтическая композиция по п.15 для лечения расстройств или патологических состояний, вызываемых нарушением питания, ожирением, булимией, неврозом, диабетом, потерей памяти, эпилептическими припадками, мигренью, расстройством сна, болями, нарушениями сексуальных/репродуктивных функций, депрессией и тревожными состояниями.16. The pharmaceutical composition according to clause 15 for the treatment of disorders or pathological conditions caused by malnutrition, obesity, bulimia, neurosis, diabetes, memory loss, epileptic seizures, migraine, sleep disorders, pain, sexual / reproductive function disorders, depression and anxiety conditions .
RU2002101935/04A 1999-07-28 2000-07-27 Derivatives of amines or amides, pharmaceutical composition based on thereof and method for antagonizing receptor y5 of neuropeptide npy RU2228927C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14606999P 1999-07-28 1999-07-28
US60/146,069 1999-07-28

Publications (2)

Publication Number Publication Date
RU2002101935A true RU2002101935A (en) 2003-08-10
RU2228927C2 RU2228927C2 (en) 2004-05-20

Family

ID=22515737

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002101935/04A RU2228927C2 (en) 1999-07-28 2000-07-27 Derivatives of amines or amides, pharmaceutical composition based on thereof and method for antagonizing receptor y5 of neuropeptide npy

Country Status (19)

Country Link
US (3) US6380224B1 (en)
EP (2) EP1493742A1 (en)
JP (1) JP2003506367A (en)
CN (1) CN1213044C (en)
AR (1) AR030676A1 (en)
AT (1) ATE306482T1 (en)
AU (1) AU783223B2 (en)
BR (1) BR0012804A (en)
CA (1) CA2380032A1 (en)
DE (1) DE60023148T2 (en)
DK (1) DK1202986T3 (en)
ES (1) ES2250170T3 (en)
HU (1) HUP0202143A3 (en)
MX (1) MXPA02000927A (en)
NO (1) NO20020384L (en)
NZ (1) NZ516782A (en)
RU (1) RU2228927C2 (en)
WO (1) WO2001009120A1 (en)
ZA (1) ZA200201660B (en)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2014285T1 (en) * 1999-11-26 2010-08-31 Shionogi & Co NPYY5 antagonists
GB0011013D0 (en) * 2000-05-09 2000-06-28 Astrazeneca Ab Chemical compounds
US7723519B2 (en) * 2001-06-07 2010-05-25 Wayne State University Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity
WO2002098367A2 (en) * 2001-06-07 2002-12-12 Wayne State University Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7459432B2 (en) * 2001-09-24 2008-12-02 Imperial College Innovations Ltd. Modification of feeding behavior
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP1496838B1 (en) * 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
AU2007201276B2 (en) * 2002-03-12 2009-11-05 Merck Sharp & Dohme Corp. Substituted amides
CA2479618A1 (en) * 2002-03-26 2003-10-09 William K. Hagmann Spirocyclic amides as cannabinoid receptor modulators
AU2003223510B2 (en) 2002-04-12 2008-05-08 Merck Sharp & Dohme Corp. Bicyclic amides
CA2486564A1 (en) * 2002-05-23 2003-12-04 Abbott Laboratories Acetamides and benzamides that are useful in treating sexual dysfunction
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
EP1575901B1 (en) 2002-12-19 2012-10-10 Merck Sharp & Dohme Corp. Substituted amides
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2222833B1 (en) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 1,4-DISPOSED PIPERIDINIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICINES.
WO2005028438A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
EP1682494A4 (en) * 2003-10-30 2006-11-08 Merck & Co Inc Aralkyl amines as cannabinoid receptor modulators
EP1719765A4 (en) * 2004-02-19 2009-01-07 Banyu Pharma Co Ltd Novel sulfone amide derivative
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US7572783B2 (en) 2004-08-13 2009-08-11 Amgen Inc. Substituted benzofused heterocycles
TW200621677A (en) * 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
ES2325773T5 (en) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Treatment of obesity and related disorders
AU2006235200A1 (en) * 2005-04-15 2006-10-19 Regenertech Pty Limited Use of Neuropeptide Y (NPY) and agonists and antagonists thereof for tissue regeneration
US7820699B2 (en) * 2005-04-27 2010-10-26 Hoffmann-La Roche Inc. Cyclic amines
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP5154927B2 (en) 2005-05-30 2013-02-27 Ｍｓｄ株式会社 Novel piperidine derivatives
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2007018248A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP1921065B1 (en) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
BRPI0616463A2 (en) 2005-09-29 2011-06-21 Merck & Co Inc compound, pharmaceutical composition, and use of a compound
CA2625416A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
JPWO2007049798A1 (en) 2005-10-27 2009-04-30 萬有製薬株式会社 New benzooxathiin derivatives
MY146564A (en) 2005-11-10 2012-08-30 Msd Kk Aza-substituted spiro derivatives
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
TWI428346B (en) * 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
JP5319518B2 (en) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 Indoledione derivative
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
JP5546451B2 (en) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド Agonyl cyclase agonists useful in the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
SA08290668B1 (en) * 2007-10-25 2012-02-12 شيونوجي آند كو.، ليمتد Amine Derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
EP2264026A4 (en) 2008-03-06 2012-03-28 Msd Kk Alkylaminopyridine derivative
CA2717384A1 (en) 2008-03-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
CN102083797B (en) 2008-04-01 2014-06-04 Abbvie公司 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2727914A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diaryl ketoxime derivative technical field
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2731358A1 (en) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
KR100905419B1 (en) 2008-09-11 2009-07-02 연세대학교 산학협력단 Uses of sesquiterpene derivatives
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
BRPI0919876A8 (en) 2008-10-30 2016-02-10 Merck Sharp & Dohme COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND, METHOD FOR ENHANCING QUALITY SLEEP, FOR TREATMENT INSOMNIA, AND FOR TREATMENT OR CONTROLLING OBESITY IN A MAMMALIAN PATIENT IN NEED THEREOF.
JP5557845B2 (en) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション Novel cyclic benzimidazole derivatives useful as antidiabetic agents
US20110230497A1 (en) * 2008-11-07 2011-09-22 H. Lundbeck A/S Biologically active amides
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
AR075442A1 (en) * 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
TW201103907A (en) * 2009-03-20 2011-02-01 Lundbeck & Co As H Amide derivatives as neuropeptide Y5 receptor ligands
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2011345201C1 (en) * 2010-12-20 2015-08-13 Hill's Pet Nutrition, Inc. Pet food compositions for inducing a satiety response
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2739614B1 (en) 2011-08-05 2017-02-22 AbbVie Deutschland GmbH & Co KG AMINOCHROMANEs, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
CN104011028A (en) 2011-11-18 2014-08-27 艾伯维德国有限责任两合公司 N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
RU2015106909A (en) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. ANTI-DIABETIC TRICYCLIC COMPOUNDS
CA2898482A1 (en) 2013-02-22 2014-08-28 Linda L. Brockunier Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3057958B1 (en) 2013-10-17 2019-05-01 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
SG11201602982YA (en) 2013-10-17 2016-05-30 Abbvie Deutschland Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
MX2019004321A (en) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase.
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
JP2022507805A (en) 2018-11-20 2022-01-18 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ α-Amino-β-carboxymuconic acid semialdehyde decarboxylase inhibitor
EP3924058A1 (en) 2019-02-13 2021-12-22 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
KR20230053639A (en) 2020-08-18 2023-04-21 머크 샤프 앤드 돔 엘엘씨 Bicycloheptane pyrrolidine orexin receptor agonists
US11926574B2 (en) 2021-06-08 2024-03-12 Atai Therapeutics Inc. Dimethoxyphenylalkylamine activators of serotonin receptors
JP2024522174A (en) 2021-06-09 2024-06-11 アタイ セラピューティクス， インコーポレイテッド Novel prodrugs and conjugates of dimethyltryptamine
WO2023129909A1 (en) 2021-12-27 2023-07-06 ATAI Life Sciences AG Aminotetraline activators of serotonin receptors
WO2023129956A2 (en) 2021-12-30 2023-07-06 ATAI Life Sciences AG Dimethyltryptamine analogues as nitric oxide delivery drugs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0258096B1 (en) * 1986-08-21 1992-09-09 Roussel-Uclaf Indane derivatives, process for their preparation, their use as medicines, pharmaceutical compositions containing them and the intermediates obtained
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
DE3718317A1 (en) * 1986-12-10 1988-06-16 Bayer Ag SUBSTITUTED BASIC 2-AMINOTETRALINE
CA2020437A1 (en) * 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
DE4319039A1 (en) * 1993-06-08 1994-12-15 Bayer Ag Substituted (2-oxo-1-benzimidazolinyl) -piperidines, process for their preparation and use as anti-retroviral agents
DE4438029A1 (en) * 1994-10-25 1996-05-02 Thomae Gmbh Dr K New N,N-di:substd. benzo-cyclo-alkylamine derivs.
WO1997019682A1 (en) * 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
US6239108B1 (en) * 1996-07-11 2001-05-29 Biogen, Inc. Cell adhesion inhibitors
AU6144098A (en) * 1997-02-14 1998-09-08 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
PL194839B1 (en) 1998-04-29 2007-07-31 Ortho Mcneil Pharm Inc N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
WO1999062505A2 (en) * 1998-06-01 1999-12-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
AU763886B2 (en) * 1998-10-07 2003-07-31 Ortho-Mcneil Pharmaceutical, Inc. N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor

Similar Documents

Publication Publication Date Title
RU2002101935A (en) Amine and amide derivatives as ligands for the neuropeptide Y receptor Y5 used to treat obesity and other disorders
RU2388750C2 (en) Inhibitors of phosphodiesterase 4 containing n-substituted diarylamine analogues
RU2436776C2 (en) DIARYLAMINE-CONTAINING COMPOUNDS, COMPOSITIONS AND USE THEREOF AS c-KIT RECEPTOR MODULATORS
RU2356893C2 (en) Phosphodiesterase 4 inhibitors
RU97100151A (en) DERIVATIVES OF PIPERAZINE AS ANTAGONISTS 5HT1A
RU2328486C2 (en) 2-pyridone derivatives as inhibitors of neutrophil elastase
RU99101350A (en) BENZOSULPHONE DERIVATIVES
RU2008123376A (en) 4- (4-ALCOXY-3-HYDROXYPHENYL) -2-pyrrolidone derivatives as PDE-4 INHIBITORS FOR TREATMENT OF NEUROLOGICAL SYNDROMES
JP2005527492A5 (en)
PL338129A1 (en) Crystalline form of a derivative of n-phenyl-2-dipyrimidin amine, methods of obtaining same and apllication thereof
KR920018022A (en) Novel indole derivatives, preparation methods thereof, and pharmaceutical products containing the same
JP2005513123A5 (en)
NZ507763A (en) N-substituted aminotetralin sulphonamide derivatives useful as ligands for the neuropeptide Y Y5 receptor used in the treatment of obesity and other disorders
RU2005111968A (en) 4-pyrrolidinophenylbenzyl ether derivatives
RU2006112593A (en) 2, 4-DI (HETERO) ARILAMINOPYRIMIDINE DERIVATIVES AS ZAP-70 AND / OR SYK INHIBITORS
CA2482346A1 (en) Substituted phenylacetamides and their use as glucokinase activators
RU2003129502A (en) COMPOUND, PHARMACEUTICAL COMPOSITION, APPLICATION, METHOD FOR PREVENTING OR TREATING DISEASES
RU2009118254A (en) PHENYLACETAMIDES AS PROTEINKINASE INHIBITORS
CA2446326A1 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
CA2396590A1 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
ES2192394T3 (en) PROFARMACOS OF PROTON PUMP INHIBITORS.
RU2003121018A (en) CARBOXAMIDE DERIVATIVES AND THEIR USE IN TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMORS
RU2003120512A (en) ACTIVATORS OF ISOINDOLIN-1-ON-GLUCOKINASE
RU2004125146A (en) NEW COMPOUNDS
RU95113149A (en) Tricyclic derivatives of pyrazole